-
1 Comment
Zivo Bioscience, Inc. Common Stock is currently in a long term uptrend where the price is trading 492.1% above its 200 day moving average.
From a valuation standpoint, the stock is 97.0% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 2639.2.
Zivo Bioscience, Inc. Common Stock's total revenue sank by 100.0% to $0 since the same quarter in the previous year.
Its net income has increased by 12.7% to $-2M since the same quarter in the previous year.
Finally, its free cash flow fell by 34.3% to $-1M since the same quarter in the previous year.
Based on the above factors, Zivo Bioscience, Inc. Common Stock gets an overall score of 2/5.
Exchange | NASDAQ |
---|---|
CurrencyCode | USD |
ISIN | US98978N2009 |
Industry | Biotechnology |
Sector | Healthcare |
Beta | None |
---|---|
PE Ratio | None |
Target Price | 12 |
Market Cap | 45M |
ZIVO Bioscience, Inc., together with its subsidiaries, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. It offers poultry gut health, avian influenza, bovine mastitis, canine joint health, human immune modification, human functional food ingredients, algal biomass for human food, and biomass for supporting skin health and anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Troy, Michigan.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for ZIVO using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025